WO2022111742A1 - Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer - Google Patents

Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer Download PDF

Info

Publication number
WO2022111742A1
WO2022111742A1 PCT/CU2021/050012 CU2021050012W WO2022111742A1 WO 2022111742 A1 WO2022111742 A1 WO 2022111742A1 CU 2021050012 W CU2021050012 W CU 2021050012W WO 2022111742 A1 WO2022111742 A1 WO 2022111742A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
compound
alzheimer
disease
acts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CU2021/050012
Other languages
English (en)
Spanish (es)
French (fr)
Other versions
WO2022111742A4 (es
Inventor
Chryslaine Rodríguez-Tanty
Marquiza SABLÓN CARRAZANA
Roberto MENÉNDEZ SOTO DEL VALLE
Alberto Bencomo Martínez
Suchitil Rivera Marrero
Laura García Pupo
Leonora GONZÁLEZ MESA
Samila LEÓN CHAVIANO
Adriana ÁGUILA CORDOVA
Kathleen CASTRO-PALOMINO ANTELA
Giselle Pentón Rol
Laura OTAÑO TAMAYO
Rafaela Pérez Perera
Majel Cervantes Llanos
Orestes de Jesús DÍAZ GARCÍA
Miriam DORESTE BROWN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centro de Neurociencias de Cuba
Original Assignee
Centro de Neurociencias de Cuba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro de Neurociencias de Cuba filed Critical Centro de Neurociencias de Cuba
Priority to CA3200071A priority Critical patent/CA3200071A1/en
Priority to US18/038,494 priority patent/US20240299334A1/en
Priority to AU2021388673A priority patent/AU2021388673A1/en
Priority to KR1020237020732A priority patent/KR20230118112A/ko
Priority to CN202180091389.3A priority patent/CN116829137A/zh
Priority to MX2023006072A priority patent/MX2023006072A/es
Priority to JP2023531700A priority patent/JP2023551249A/ja
Priority to EP21848149.7A priority patent/EP4252749A1/en
Publication of WO2022111742A1 publication Critical patent/WO2022111742A1/es
Publication of WO2022111742A4 publication Critical patent/WO2022111742A4/es
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Definitions

  • the present invention is related to Pharmaceutical Chemistry and refers to the pharmaceutical composition of the compounds of Formula I, which show multitarget action on the different mechanisms of the cholinergic, glutamatergic and mitochondrial systems that are affected in Alzheimer's Disease ( AE).
  • the formulation of these compounds increases efficacy and tolerance through oral, sublingual, parenteral, transdermal and nasal administration.
  • This invention is particularly useful to provide an effective formulation, in which the compounds of Formula I, their salts, hydrates, enantiomers, isomers, metabolites, prodrugs for administration to humans, are considered as active substance or principle for the treatment of EA.
  • AD Alzheimer's Disease
  • AD Alzheimer's disease
  • ⁇ A p-Amyloid peptides.
  • tau protein p-Amyloid peptides.
  • amyloid fibers or plaques sequentially generates the activation of the complement, of microglia, the release of cytokines (chemokines), and finally, diffuse neurotoxicity (Reitz C. in International Journal of Alzheimer's disease. 2012 Jan; 2012:369808; Rodrigue K. in Neuropsychol Rev. 2009 December; 19(4): 436-450. doi: 10.1007/s11065-009-9118-x; Bateman, RJ et al.
  • phagocytic system made up of infiltrating macrophages and monocytes attached to resident microglia cells, produces excessive amounts of cytokines such as tumor necrosis factor ⁇ (TNF ⁇ ), interleukin 1 (IL1), as well as reactive oxygen species (EROS) and nitrogen (ENOS), which are involved in AD.
  • TNF ⁇ tumor necrosis factor ⁇
  • IL1 interleukin 1
  • EROS reactive oxygen species
  • ENOS reactive oxygen species
  • This set of responses to given stimuli triggers a vicious circle of aggressions that is sustained by the localized glial cells, which cause a phagocytic attack that damages irreversibly to neurons
  • Malm TM in Neurotherapeutics 2015, 12:81-93; ElAli A. et al. in Brain, Behavior, and Immunity, 2015, doi: 10.1016/j.bbi.2O15.07.021; Michaud J.- P. et al., in Neuron, 85, 4,
  • Mitochondrial dysfunctions are described as an early event in the pathophysiology of AD and appear before ⁇ A deposition and memory deficits in AD patients and in transgenic mice (Maurer, /., et al. in Neurobiol. Aging 2000, 21, 455-462; Caspersen, C. et al. in FASEB J. 2005, 19, 2040-2041; Mosconi, L et al. in Ann. N Y Acad. Sci. 2008, 1147, 180-195).
  • ⁇ A oligomers accumulate in mitochondria, leading to impaired energy metabolism, increased oxidative stress (OS), and apoptosis (Lustbader, et al.
  • a possible mechanism of mitochondrial dysfunction is related to mitochondrial permeability transition pore (mPTP) opening, which may be triggered by Ca 2+ overload and EO (Kroemer, G. and Reed, JC in Nat. Med. 2000, 6, 513-519) and that induces the release of proapoptotic factors, such as the proapotic protein Bax that contributes to the formation of mPTP (Jürgensmeier, JM, et al. in Proc. Natl. Acad. Sci. USA, 1998, 95, 4997-5002; March, /., et al. in Science 1998, 281, 2027-2031; Narita, M., et al in Proc Nati Acad Sci USA 1998, 95, 14681-14686).
  • mPTP mitochondrial permeability transition pore
  • cytochrome c which promotes apoptosis, is released by binding to apoptosis protease activating factor (APAf-1) and forming a complex known as "apoptosome" (Liu, X., et al. in Cell 1996, 86, 147-157; Yang, J., et al. in Science 1997, 275, 1129-1132).
  • APAf-1 apoptosis protease activating factor
  • AD Alzheimer's disease
  • acetylcholinesterase inhibitors AChEl
  • NMDAr N-methyl-D-aspartic acid receptor antagonists
  • AChELs are donepezil, rivastigmine, and galantamine. Their mechanism of action is to increase cholinergic transmission by inhibiting acetylcholinesterase in the synaptic cleft and, therefore, they could increase the cognitive capacity of AD patients.
  • AChEl are available in various formulations that include immediate release forms, such as tablets, capsules and solutions, as well as controlled release forms for oral administration, among others (Villegas S. en Medicina Cl ⁇ nica, 2015, 145, 2 , 76-83).
  • these AChEls offer only modest clinical benefit for some patients, even when these drugs are administered at their maximum safe and tolerable doses.
  • these compounds cause side effects that include anorexia, nausea, vomiting, diarrhea, abdominal pain, and weight loss (in Physicians Desk Reference 2008, Thomson PDR et al. in Clinical Geriatrics: Volume 2011, 19, 1; All T. et al in PLOS ONE, 2015, 7, 1-10; Tsoi KKF in JAMDA, 1-7, 2015, doi: 10.1016/j.jamda.2015.08.007).
  • NMDAr are ionotropic receptors for glutamate, a neurotransmitter that acts as an essential component in neuronal synaptic plasticity and memory.
  • Memantine an antagonist of these receptors, is used in clinical practice for its neuroprotective effect indicated in moderate to severe AD (National Institute for Clinical Excellence. Technology appraisal guidance 217. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease at www.nice.ong.uk/guidance/TA217 O'Brien JT, et al in J Psychopharmacol Oxf Engl 2011;25:997-1019 Francis PT et al in Trends Pharmacol Sci 2005;26 : 104-11; Huang Y et al. in Cell.
  • Lipid-lowering agents such as statins (Home-ClinicalTrials.gov [Accessed 21 March 2016]. Available at: http://www.clinicaltrials.gov/. Wong WB. et al. in Pharmacoepidemiol Drug Saf. 2013; 22: 345 -58; Frolich L, et al in J Alzheimers Dis. 2011;24:363-74.)
  • Carrazana et al. declare the synthesis of new neutral, lipophilic and low molecular weight compounds that cross the blood-brain barrier (BBB) and adhere to amyloid plaques, and that are used as diagnostic agents, through the techniques SPECT, PET and MRI, for the visualization of these structures.
  • BBB blood-brain barrier
  • these compounds can be used as therapeutic agents for Alzheimer's and Parkinson's diseases.
  • these authors declare in WO2014131374 A1, the use of these compounds as therapeutic agents for this disease because they can: inhibit, reduce, refold, disaggregate soluble oligomers, prefibrillar structures, protofibrils and amyloidogenic fibers, as well as amyloid plaques .
  • the active ingredient is uniformly distributed within a polymer, either as a suspension or as a solution, and its release kinetics will depend on the structure of the matrix and the chemical nature of the materials used (Frenkel, J., in Rubber Chemistry and Technology, 1940, 13, 264-274; Tanaka et al. in Encyclopedia of Polymer Science, 1986, 2nd edn 6, 514; Fyfe, CA, Blazer, AI, in Journal of Controlled Release, 1998, 52, 221-225).
  • the delayed or modified action excipients used to formulate matrix tablets may be inert or insoluble polymer matrices, water-insoluble or lipid matrices, or hydrophilic matrices.
  • Hydrophilic matrices are obtained by mixing the active ingredient with hydrophilic polymers, which gives rise to polymeric matrices.
  • Cellulose ethers are hydrophilic polymers widely used in the development of controlled release systems, as they are biologically compatible and non-toxic.
  • hydroxypropylmethylcellulose HPMC
  • HPMC hydroxypropylmethylcellulose
  • HPC hydroxypropylcellulose
  • CMC- Na sodium carboxymethylcellulose
  • MC methylcellulose
  • EC ethylcellulose
  • microcrystalline cellulose polysaccharides and their derivatives polyalkylene oxides, polyethylene glycols, chitosan, poly(vinyl alcohol), xanthan gum, maleic anhydride copolymers, poly(vinyl pyrrolidone), starch and starch-based polymers, maltodextrins, poly(2-ethyl-2-oxazoline), poly(ethyleneimine), hydrogels of polyurethane, cross-linked polyacrylic acids and their derivatives.
  • HPMC hydroxypropylmethylcellulose
  • HPC hydroxypropylcellulose
  • CMC- Na sodium carboxymethylcellulose
  • MC methylcellulose
  • EC ethylcellulose
  • microcrystalline cellulose polysaccharides and their derivatives polyalkylene
  • the nasal mucosa and the mucus layer contain a wide variety of enzymes, so several techniques have been tried to prevent enzymatic degradation, including the use of protease and peptidase inhibitors (Pires, A , et al in J Pharm Pharmaceut Sci 2009;12(3):288-311). Also, there are absorption promoters that produce reversible modifications of the epithelial barrier, increase the permeability of this barrier by modifying the lipid membrane, increase its fluidity, or open the intercellular spaces, which increases paracellular transport.
  • Mucoadhesive compounds allow the pharmaceutical form to bind to the mucosal layer, which increases the contact time between the mucosa and the drug, and favors absorption.
  • These include agarose, chitosan, gelatin, carrageenan, pectin, cellulose derivatives, polyacrylates, PEG, methacrylate, acrylic acid, PVA aminodextran, chitosan-EDTA, PAC, alginate, carboxymethylcellulose and its sodium form (CMC and Na-CMC), hydroxyethylated starch, polyvinylpyrrolidone (PVP), thiolated polymers, polyacrylic acid, (Mansuri, S. etal. in React. Funct. Polym. 100 (2016) 151- 172).
  • the intranasal route can be used for the transport of drugs of low molecular mass (less than 1000 Da) (Behl CR, et al. in Adv Drug Del Rev 1998; 29(1): 89-116).
  • drugs of low molecular mass less than 1000 Da
  • Behl CR, et al. in Adv Drug Del Rev 1998; 29(1): 89-116 Different approaches to delivery of these small molecules to the CNS are stated in several patents.
  • Quay, S. C. et al. (in US20030225031A1 (2003) and in US20060003989A1 (2006)) claim pharmaceutical compositions for the treatment of dementia, AD, learning disorders, nicotine withdrawal syndrome due to acetylcholinesterase inhibitors (donepezil, tacrine, rivastigmine, galantamine, among others), which comprises a liquid solution, gel or powder for nasal administration of the drug and a permeability enhancer for transmucosal absorption of the drug into the CSF by intranasal administration.
  • acetylcholinesterase inhibitors donepezil, tacrine, rivastigmine, galantamine, among others
  • a permeability enhancer for transmucosal absorption of the drug into the CSF by intranasal administration.
  • Went GT et al in US20050245617A1 (2005) claim a pharmaceutical composition of an N-methyl-D-aspartate (NMDA) receptor antagonist (memantine), a monoamine oxidase (MAO) inhibitor or a GADPH inhibitor (selegiline ); and an acceptable pharmaceutical carrier, the composition of which is administered as a sustained-release dosage form for oral, topical transepithelial, subdermal, intravenous, intranasal, or inhalation administration for the treatment of CNS-related conditions, such as Parkinson's disease, multiple sclerosis and AD.
  • NMDA N-methyl-D-aspartate
  • MAO monoamine oxidase
  • GADPH inhibitor a GADPH inhibitor
  • the present invention is related to Pharmaceutical Chemistry and refers to the pharmaceutical composition of the compounds of Formula I, which show multitarget action on the cholinergic, glutamatergic and mitochondrial systems that are affected in Alzheimer's Disease (AD).
  • the formulation of these compounds increases efficacy and tolerance through oral, sublingual, parenteral, transdermal and nasal administration.
  • R 1 -alkylenyl-C(O)NH-alkylenyl- R 3 , -alkylenyl-C(O)OR 4 ;
  • R 3 -COOH, -OH, -SH, -NH 2 , -NH-alkyl-, -NH-alkylenyl-NH 2 , -NH-alkylenyl- NH-C(O)-alkylenyl-SR 5 , -NH- dithiocarbamate-alkyl, -N-alkyl- dithiocarbamate alkaline earth metal salts; or pharmaceutically acceptable salts of the aforementioned groups.
  • R 4 succinimidyl group
  • R 5 -H, -C(O)-alkyl, -C(O)-C 6 H 5 ;
  • R 2 -H, -alkyl.
  • alkyl is characterized by being a linear or branched aliphatic chain of saturated carbon atoms and hydrogen atoms, preferably methyl or ethyl.
  • alkylenyl refers to a divalent analog of a linear or branched alkyl group, preferably methyleneyl (-CH 2 -), ethyleneyl (-CH 2 CH 2 -), or propylenyl (-CH 2 CH 2 CH 2 -).
  • the formulated compounds of Formula I can be used by themselves to replace the multitherapy that is used today, where a combination of several active ingredients is used to improve AD symptoms.
  • the compounds of Formula I individually present anticholinergic, antioxidant, antiglutamatergic and anti-inflammatory activity, which makes them powerful active ingredients for AD monotherapy. Furthermore, they are capable of inhibiting amyloidogenic peptide aggregation and plaque formation (in WO2010118706 A4). With this, the patient receives a monotherapy, with which there is a significant improvement in the clinical symptoms and the biological alterations present in the brain of the subjects suffering from AD.
  • the formulation that is presented of the compounds of Formula I, their salts, hydrates, enantiomers, isomers, metabolites, prodrugs for their administration to humans, as active substances or principles for the treatment of AD, allows to increase the bioavailability, the time of residence of the active ingredient, and adequate excretion, which increases the efficacy, biosafety, adherence and tolerance to treatment, through oral, sublingual, parenteral, transdermal and nasal administration.
  • the compounds of Formula I can be conveniently prepared as described in Cuban patent No. 2009-57, PCT-CU2010-000001.
  • Figure 2 shows the effect of compound 1 on the dissipation of the mitochondrial membrane potential ( ⁇ ⁇ ), related to the flow of electrons through the protein complexes of the electron transport chain (ETC).
  • ETC electron transport chain
  • Mitochondria treated with ethylene-bis (oxyethylenenitrile) tetraacetic acid (EGTA) show the least dissipation of mitochondrial potential, as this was the control group of the experiment.
  • EGTA acts as a chelator of the Ca 2+ contaminant of the reaction medium, so that the mitochondria are in their best state and retain their potential to the maximum.
  • the EGTA control + carbonyl cyanide 3-chlorophenyldrazone (CCCP) is the group where mitochondrial damage occurs, because CCCP dissipates ⁇ ⁇ by acting as an uncoupler of oxidative phosphorylation.
  • Compound 1 in the concentration range of 0.1 ⁇ mol/L to 100 ⁇ mol/L shows potential dissipation values similar to the control group (EGTA). According to these results, compound 1, in the dose range tested, decreases the susceptibility to potential dissipation.
  • Figure 3 shows the results of the evaluation of the mitochondrial swelling induced by 50 ⁇ mol/L of Ca 2+ and 2 mmol/L of inorganic phosphate (Pi), which was evaluated spectrophotometrically from the decrease in the absorbance at 540nm.
  • the maximum absorbance values are shown, as a measure of the maximum swelling.
  • the samples treated with EGTA showed low absorbance values (p ⁇ 0.001), as this was the undamaged control.
  • the group treated with CCCP also shows low absorbance values (p ⁇ 0.001), since uncoupling prevents the entry of Ca 2+ ions, and thus prevents mitochondrial swelling.
  • Compound 1 at similar concentrations reverses the effect of swelling induced by Ca 2+ , so it can be considered a protector of mitochondrial integrity and functionality.
  • the compounds of Formula I interact with the enzyme AChE in a similar manner as donepezil. These interactions are of the hydrophobic type with the amino acids Trp 84, Trp 279 and Phe 330. Similarly, these compounds interact with all the serine residues in the cavity involved in the reaction with acetylcholine, by forming three hydrogen bonds that provide stability to the ligand/enzyme bond, suggesting that the compounds may block enzyme activity.
  • the Scopolamine (ESC)-induced amnesia model is one of the most widely used to induce cognitive deficits associated with dementia and aging (Bajo R, et al. Scientific reports 2015, 5: 9743; Gilles C and Ertle S.
  • the use of this nonselective competitive antagonist of muscarinic cholinergic receptors is an effective way of blocking cholinergic neurotransmission and thus inducing dementia.
  • ESC induces an increase in the activity of the enzyme acetylcholine esterase (AChE for Acetylcholine esterase) which, together with the blockade of receptors, contributes to the deficit of cholinergic neurotransmission.
  • This model is used in in vivo tests of those agents that inhibit enzyme activity, such as donepezil (Shin CY, etal.
  • Behavioral assessment in the acute ESC model was performed using the "spatial version" of the Y-maze, which assesses short-term spatial memory (McGaugh J.L, in Science, 153 (1966) 1351), and is based on the ability to animals to spontaneously recognize new spaces within the labyrinth. Memory tested in this protocol involves hippocampal function (Csiszar A, et al. in Am. J. Physiol. Heart Gire. Physiol. (2013), 305 H1120-1130; Olton D.S. and Paras B.C., in Neuropsychologia, 17 (1979) 669-682.)
  • Figure 5 shows the results of the behavioral test in the Y maze of the compound methyl (2- ⁇ [4-(1-naphthylamino)-4-oxobutanoyl]amino ⁇ ethyl)dithio carbamate (3), evaluated in the ESC model.
  • the animals of the control group have a preference for the novel arm, which was evidenced by a significant decrease in the time spent in the two familiar arms (p ⁇ 0.001).
  • This behavioral profile preference! was not reproduced with ESC administration 30 minutes before training. In this case, the time spent in the novel arm decreased, with no statistically significant differences being observed with respect to the other two arms.
  • the criterion that is evaluated is the difference and/or the quotient of the escape latencies: that of the last training test with the visible platform and that of the first test with the hidden platform (24 h later).
  • animals that develop a correct spatial strategy move rapidly toward the hidden platform area, indicating that they maintain intact long-term memory capacity.
  • animals that take time to locate the hidden platform have errors in long-term spatial memory, with longer escape latencies.
  • Figure 7 shows the results of the behavioral evaluation of compound 3 in the acute ESC model using the MWM.
  • the results indicate that the mice administered with ESC have long-term spatial memory deficits, but not those treated with compound 3.
  • the arithmetic difference, as well as the ratio of the latency time of the last training test with the visible platform and that of the first test with the hidden platform show that the group treated with compound 3 differs significantly from the group with ESC.
  • the results of this experiment confirm those obtained in previous experience on short-term spatial memory.
  • AChE activity ( ⁇ mol/L/min/mg of protein) was determined ex vivo, in samples of the soluble fraction of brain homogenates ( Figure 8, Non-limiting Example 3). The results show that there was a significant (p ⁇ 0.001) increase in AChE activity in the ESC-treated group compared to the control group. However, AChE activity was surprisingly significantly reduced in the 3-treated group (p ⁇ 0.05), compared to the ESC group, and as expected in the donezepil-treated group (p ⁇ 0.01).
  • the chronic ESC model has recently emerged as another alternative in the experimental evaluation of new agents for the treatment of AD (Klinkenberg I and Blokland A, in Neurosci Biobehav Rev 2010, 34(8):1307-1350).
  • cognitive dysfunction is induced by administering serial doses of ESC (ip) for 10 consecutive days, at the rate of once daily administration.
  • ip serial doses of ESC
  • a degeneration of the cholinergic system occurs, such as; increase of the activity/expression of acetylcholinesterase, a decrease in the activity/expression of the cholineacetyltransferase synthesis enzyme and a deficit in the active consumption of choline at the level of the presynaptic terminal (Haider, S. et al. in Brain research bulletin, 2016, 127 , 234-247).
  • Amyloid precursor protein ApPP
  • ⁇ A aggregates and hyperphosphorylated tau Bihaqi SW, et al. in Indian J. Pharmacol. 2012, 44(5): 593-598; Ramandeep K , et al., in Int J Prev Med Res. 2015. Vol. 1, No. 2, pp. 45-64).
  • Figure 9 shows the results of behavioral evaluation of long-term memory of compound 3 in the chronic ESC model (daily dose of 1.5 mg/kg, 2 weeks).
  • Compound 3 was given three days prior to ESC administration and for the following two weeks of ESC.
  • the MWM results indicate the memory deficit of ESC-administered mice.
  • the ratio of the first escape latency of the test with the hidden platform (T7) and the last test with the visible platform (T6 ) significantly decreases compared to the ESC group.
  • the results indicate that the dose of 1 mg/kg behaves as the maximum effect dose.
  • the results show that in this model a degeneration of the cholinergic system is induced, evidenced by the detriment of long-term spatial memory in the MWM, which is prevented with the use of compound 3.
  • glutamate receptor-mediated excitotoxicity may underlie the pathophysiology of a number of neurological abnormalities, including AD and Parkinson's disease (PD).
  • glutamate plays a central role in neurological development, transmission and synaptic plasticity.
  • this neurotransmitter is involved in memory and learning processes.
  • glutamate concentrations rise in brain tissue in response to different noxes, and this phenomenon triggers the neuronal death, especially due to increased intracellular Ca 2+ concentrations.
  • Excitotoxic cell death is also affected by other receptors of the glutamatergic system.
  • AK kainic acid
  • AMPA ⁇ -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
  • AK administration in rodents is known to induce recurrent seizures, behavioral changes, and subsequent degeneration of neurons, specifically of the CA1 and CA3 regions of the hippocampus (Wang Q, et al. in Mol Neurobiol. 2005, 31:3-16) .
  • AK-induced neuronal death is accompanied by increased activation of microglia and astrocytes, increasing the generation of inflammatory cytokines (Cr ⁇ en, Z.et al. in J. Neurobiol., 2005, 62(2), 207-218) .
  • the activation of AK receptors produces depolarization of the mitochondrial membrane and, as a result, the alteration of intracellular Ca 2+ concentrations (Brorson, JR et al. in J. Neuroso!., 1994, 14(1), 187-197).
  • damage to mitochondrial function is induced (Wang Q,. et al. in Mol.
  • the compounds of Formula I have not been formulated so far, so the pharmaceutical compositions of this invention are unique, which take into consideration the physical-chemical properties of these compounds and, in a singular way, the weight ratios of the ingredients in The compositions.
  • the formulations presented guarantee the properties of these multitarget therapeutic agents with anticholinergic, antioxidant, antiglutamatergic, and anti-inflammatory action.
  • These formulations allow a sustained dose over time of effective plasma concentrations of the active ingredient, which ensure its efficacy, which has not been described so far, and allow increased adherence and tolerance through oral, sublingual, parenteral, transdermal and nasal administration. .
  • compositions of the compounds of Formula I, their salts, hydrates, enantiomers, isomers, metabolites, prodrugs for administration to humans, of the present invention include suitable excipients and may be in solid, semi-solid, gelatinous or liquid form, such as: tablets, capsules, suspensions, emulsions, parenteral solutions, transdermal patches, nasal solutions, mucoadhesives, among others.
  • the formulation will contain from 0.1 to 99%, preferably from 1 to 80%, of active compound, together with the carrier or components of the formulation.
  • Excipients are liquid, solid or semi-solid auxiliary substances, compounds of an organic and inorganic nature, of natural origin or synthetic, physiologically acceptable and commonly used in the formulation of active ingredients.
  • a pharmaceutical form of choice in this invention is tablets, to be administered at least once a day and contain a therapeutically active ingredient selected from the group of compounds of Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. solid, semi-solid, gelatinous or liquid polymeric matrix.
  • the dosage forms of the invention sustain release of the therapeutically active agent between 2 to 24 hours when said form is exposed to aqueous solutions. After the administration of said formulation, the rate of dissolution of the active ingredient is more than 80% between 6 and 18 hours, and the effective plasma level of the drug is maintained for 24 hours.
  • the active ingredient is present in amounts of from about 1 to 100 mg per formulation.
  • the tablets particularly, use as polymers: polyethylene oxide, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), sodium carboxymethylcellulose (CCNa), cellulose derivatives, Eudragit RS PO, polyvinylpyrrolidone or combinations thereof.
  • HPMC hydroxypropylmethylcellulose
  • HPC hydroxypropylmethylcellulose
  • HPC hydroxypropylcellulose
  • CCNa sodium carboxymethylcellulose
  • cellulose derivatives cellulose derivatives
  • Eudragit RS PO polyvinylpyrrolidone or combinations thereof.
  • the polymer is present in amounts ranging from 5% w/w to 80% w/w, preferably from 10% to 70% w/w.
  • the polymer is preferably present at 5% w/w to 50% w/w.
  • the formulations are prepared in the conventional manner described in the literature.
  • Figures 12, 13 and 14 show the controlled release profiles of the three tablet formulations, which should not be considered as limiting this invention (Examples 7, 8 and 9), for obtaining tablets of the active ingredients : (N-[4-(1-naphthylamino)-4-oxobutanoyl]- ⁇ -alanine (1), 6- ⁇ [4-(1-naphthylamino)-4-oxobutanoyl]amino ⁇ hexanoic acid) (2) and methyl (2- ⁇ [4-(1-naphthylamino)-4-oxobutanoyl]amino]ethyl)dithio carbamate (3).
  • formulations contain 10 mg of active ingredient, and other additives such as starch as a binder, microcrystalline cellulose as a disintegrant, lactose as a diluent, silicon dioxide as a glidant and magnesium stearate as a lubricant, in different proportions and the following polymeric matrices were used: HMPC, HPC and Eudragit RS PO.
  • Figures 12, 13 and 14 show that in the three formulations two release phases are produced depending on the pH of the medium.
  • the release of the active ingredients from the matrix was not significant, with less than 1% of the principle released. .
  • the tablet formulations of the compounds of Formula I of this invention have an optimal release profile. It uses accessible polymeric matrices so that the tablets can be produced in a simple and economical way with the incorporation of physiologically compatible components, which provides extended-release compositions in two phases, which facilitate dosage, without producing adverse side effects.
  • the transdermal system developed in this invention is made up of the following successive layers: a) lipophilic protective outer layer; b) layer containing the active ingredient of Formula I, in the form of a gel, suspension, emulsion, or other; where the compound is incorporated into a matrix (which can be acrylic), which ensures its effective storage; c) bifacial controlling membrane that releases the active ingredient; d) release module, which includes an active ingredient reservoir and a drug release control system and is generally made up of a polymeric material (carboxymethylcellulose (CMC), ethylcellulose, gelatin, methylcellulose, starch, etc.; synthetic elastomers: polybutadiene, polyisoprene, neoprene, polysiloxane, etc.
  • CMC carboxymethylcellulose
  • elastomers polybutadiene, polyisoprene, neoprene, polysiloxane, etc.
  • hypoallergenic adhesive layer which allows the patch to be fixed by pressure and contains polymers acrylics, hypoallergenic silicone, resins, mineral oils, polyisobutylene, etc. and f) internal protective sheet, which is removed before applying the system to the skin.
  • the coating on these topical patches ensures a smooth, continuous release of the drug through the skin into the bloodstream; no adverse reactions.
  • Two types of patches are declared, according to their size and dosage capacity. One with an area of 5 cm 2 , a dose of 5 mg of active ingredient and release of 4 mg/day of compound. Another with doubled proportions and capacity. Therapy begins with a daily dose of the smaller patch, and after good tolerance and a minimum of 4 weeks, the larger patch (10 cm 2 , 10 mg/24 h) is applied.
  • the nasal formulation of the compounds of Formula I, their salts, hydrates, enantiomers, isomers, metabolites, prodrugs for administration to humans, of the present invention employs different components that function as solvent, bioadhesive, preservative, antioxidant and surfactant/humectant.
  • bioadhesive excipients can be: hydroxypropylmethylcellulose (HMPC), hydroxypropylcellulose (HPC), methylcellulose (MC), carboxymethylcellulose (CMC), all of them with concentrations from 0.5 to 7% and derivatives of polyacrylic acid (carbol) from 0.01 to 1.5%.
  • HMPC hydroxypropylmethylcellulose
  • HPC hydroxypropylcellulose
  • MC methylcellulose
  • CMC carboxymethylcellulose
  • PEG is used as solvent for the active ingredients.
  • Bioadhesive polymers present, non-limiting way, a viscosity of 10 to 60 mPas, with the aim of increasing the residence time in the nasal cavity.
  • Benzalkonium chloride from 0.005 to 0.5% or in combination with disodium EDTA, in concentrations from 0.002 to 0.2% and propylparaben from 0.005 to 0.05%, is preferably used as an antimicrobial preservative excipient.
  • the pH was adjusted between 6 and 7.5 using isotonic solutions of phosphate or citrate buffers.
  • Isotonizing agents can be: sodium chloride, mannitol, sorbitol, glucose, among others.
  • the antioxidant used preferably is tocopherol from 0.05 to 2%.
  • Glycerol from 3 to 6%
  • Tween 80 from 0.1 to 0.4% are used as wetting agents, which allow increasing permeability.
  • the solvent used in all cases was water for injection.
  • Intranasal administration is considered a method of delivering therapeutic agents to the central nervous system (CNS).
  • Drug release occurs within minutes along olfactory pathways and trigeminal neural pathways, extracellular routes that do not require drug binding to any receptor or axonal transport system (Thome, R.G. et al. in Neuroscience. 2002, 127, 481-496).
  • Figure 15 shows the results of behavioral evaluation (Y-maze test) of the effect of administration of the nasal formulation of compound 3 on amnesia induced by acute administration of ESC.
  • Y-maze test behavioral evaluation
  • Figure 1 Structures and physical-chemical properties of some of the compounds of Formula I selected for the non-limiting examples of this invention.
  • Figure 2 Effect of the compound of Formula I (N-[4-(1-naphthylamino)-4-oxobutano ⁇ l]-p-alanine (1) on the membrane potential of mitochondria isolated from rat liver.
  • Figure 3 Effect of compounds of Formula I (N-[4-(1-naphthylamino)-4- oxobutanoyl]- ⁇ -alanine (1) on the swelling of mitochondria isolated from rat liver. ***p ⁇ 0.001 Comparison vs. control using the t-Student test A p ⁇ 0.05 was considered as a statistically significant difference.
  • Figure 4 Effect of the compounds of Formula I (N-[4-(1-naphthylamino)-4-oxobutanoyl]- ⁇ -alanine (1) on the production of reactive oxygen species in mitochondria isolated from rat liver. ***p ⁇ 0.001. Comparison against the EGTA group using the t-Student test. A p ⁇ 0.05 was considered as a statistically significant difference.
  • Figure 5 Anticholinergic modulatory effect of the compound methyl (2- ⁇ [4-(1-naphthylamino)-4-oxobutanoyl]amino ⁇ ethyl)dithio carbamate (3) in a model of memory loss induced by acute administration of scopolamine ( ESC). Spatial short-term memory in the Y-maze after the acquisition session of the control groups, ESC and treated at simple doses with 3 (0.1, 1, 10 and 20 mg/kg, i.p.). * p ⁇ 0.05, ** p ⁇ 0.01, ***p ⁇ 0.001. One-way analysis of variance followed by Turkey's post-hoc test.
  • Figure 6 Anticholinergic modulatory effect of the compound methyl (2- ⁇ [4-(1-naphthylamino)-4-oxobutanoyl]amino ⁇ ethyl)dithio carbamate (3) in a model of memory loss induced by acute administration of scopolamine ( ESC).
  • Figure 7 Anticholinergic modulatory effect of the compound methyl (2- ⁇ [4-(1-naphthylamino)-4-oxobutanoyl]amino ⁇ ethyl)dithio carbamate (3) in a model of memory loss induced by acute administration of scopolamine ( ESC).
  • Upper panel MWM performance in the two-day protocol of the different experimental groups.
  • Lower panels Long-term spatial memory, escape latency from the last trial with the visible platform (D1T4); escape latency of the first trial with the visible platform (D2T1).
  • Figure 8 Anticholinergic modulatory effect of the compound methyl (2- ⁇ [4-(1-naphthylamino)-4-oxobutanoyl]amino ⁇ ethyl)dithio carbamate (3) in a model of memory loss induced by acute administration of scopolamine ( ESC). Anticholinesterase activity in soluble fractions of animal brain homogenates from the acute ESC model of the control group, ESC-treated group, and methyl (2- ⁇ [4-(1-naphthylamino)-4-oxobutanoyl]amino ⁇ -treated groups ethyl)dithiocarbamate (3) and donezepil.
  • Figure 9 Anticholinergic modulating effect of the compound methyl (2- ⁇ [4-(1-naphthylamino)-4-oxobutanoyl]amino ⁇ ethyl)dithio carbamate (3) in a model of memory loss induced with the use of chronic Scopolamine.
  • Figure 10 Neuroprotective effect of the compound methyl (2- ⁇ [4-(1-naphthylamino)-4-oxobutanoyl]amino ⁇ ethyl) dithiocarbamate (3) on glutamate-induced excitotoxic damage in the SH-SY5Y cell line.
  • SH-SY5Y cells were treated with different concentrations of compound 3 (1-8-60 ⁇ mol/L), for 24 hours, then the medium was replaced with fresh medium containing the compound again and 60 mmol/L glutamate.
  • Figure 11 Neuroprotective effect of the compound methyl (2- ⁇ [4-(1-naphthylamino)-4-oxobutanoyl]amino ⁇ ethyl)dithio carbamate (3) on seizures induced by icv administration of kainic acid, expressed as final scores (0-120 minutes) of the different groups of animals.
  • *p ⁇ 0.05; **p ⁇ .001.
  • Figure 12 Release profiles of Formulation 1 of tablets of the compounds: (N-[4-(1-naphthylamino)-4-oxobutanoyl]- ⁇ -alanine (1) and methyl (2- ⁇ [4-(1 - naphthylamino)-4-oxobutanoyl]amino ⁇ ethyl)dithio carbamate (3), without enzymes at pH 1.2, at pH 7.5 and at a change in pH from 1.2 to 7.5, for 18 hours.
  • Figure 13 Release profiles of Formulation 2 of tablets of the compounds: 6- ⁇ [4-(1-naphthylamino)-4-oxobutano ⁇ l]am ⁇ no ⁇ hexanoic acid) (2) and methyl (2- ⁇ [4-(1-naphthylamino)-4-oxobutanoyl]amino ⁇ ethyl)dithio carbamate (3), without enzymes at pH 1.2, at pH 7.5 and at a change in pH from 1.2 to 7.5, for 18 hours.
  • Figure 14 Release profiles of Formulation 3 of tablets of the compound: methyl (2- ⁇ [4-(1-naphthylamino)-4-oxobutanoyl]amino ⁇ ethyl)dithio carbamate (3), without enzymes at pH 1.2, at pH 7.5 and at a change in pH from 1.2 to 7.5, for 18 hours.
  • Figure 16 Effect of intranasal single dose administration (74 pg/kg) of compound 3 on amnesia induced by acute administration of scopolamine (1.5 mg/kg, ip) in the object discrimination test.
  • Example 1 Evaluation of the effect of the compound of Formula 1 (N-[4-(1-naphthylamino)-4-oxobutanoyl]- ⁇ -alanine (1) on membrane potential, swelling and production of reactive oxygen species in mitochondria isolated from rat liver.
  • Mitochondria were isolated by the classical method of differential centrifugation from the liver of male Wistar rats (Mirella SR, et al., in J Neurosci Res 2010;88:630-39).
  • Mitochondria were energized with 5 mmol/L potassium succinate (plus 2.5 ⁇ mol/L rotenone) in standard incubation medium containing 125 mmol/L sucrose, 65 mmol/L KCl, and 10 mmol/L KCl. L of HEPES-KOH, pH 7.4, at 30°C.
  • Mitochondrial membrane potential and EROS were determined by spectrophotometry, using safranin (10 ⁇ mol/L) as fluorescent probes, respectively (Zanotti A., and Azzone G.F. in Archives of Biochemistry and Biophysics 1980, 201(1), 255-265) and Amplex Red (Molecular Probes, OR, Eugene) in the presence of horseradish peroxidase (1 IU/mL) (Votyakova and Reynolds, in J Neurochem. 2001, 79(2), 266-77). Measurements were made in a Hitachi fluorescence spectrophotometer, model F-4500.
  • Example 2 Evaluation of the anticholinergic modulating effect of the compound methyl (2- ⁇ [4-(1-naphthylamino)-4-oxobutanoyl]amlno ⁇ ethyl)dithio carbamate (3) in a model of memory loss induced with the acute use of Scopolamine.
  • the animals were randomly distributed according to their body weights in 5 experimental groups of 12 animals per group.
  • scopolamine hydrobromide (ESC, Sigma Aldrich) was used, which was dissolved in saline solution. physiological and was administered intraperitoneally (ip) at a dose of 1.5 mg/kg, 30 minutes before the test (Miranda HFet al. in. J. Biomed. Sci., 201421(1): 62-62).
  • the doses used for compound 3 were 0.1, 1, 10 and 20 mg/kg of body weight.
  • the compound was formulated using carboxymethylcellulose (CMC).
  • CMC carboxymethylcellulose
  • Group 1 (negative control) with normal cognitive function. Two administrations with an interval of 30 minutes with vehicle (CMC 5%) orally and saline solution by i.p. route, respectively.
  • Group 2 (positive control) with cognitive dysfunction. Two administrations with an interval of 30 minutes, the first with vehicle (CMC 5%), the second with ESC 1 mg/kg.
  • Group 3, 4, 5 and 6 treated with 3 (0.1, 1, 10 and 20 mg/kg). Two administrations with an interval of 30 minutes, the first with 3 at the dose corresponding to each group, the second with ESC 1 mg/kg. The behavioral evaluation was performed 30 minutes after this second administration.
  • the study of short-term spatial memory was carried out through the study of novel spatial preference, using the Y-maze behavioral paradigm (40 cm long x 9 cm wide x 16 cm high) with extra labyrinthine clues around of the labyrinth.
  • the test consisted of two trials separated by an interval of 2 h.
  • the mice were placed in the center of the maze and facing the end of one of the arms whose selection was random. After being placed, they were allowed to explore the maze for 10 minutes with one of the arms closed (novel arm). At the end of this trial, the mice were returned to their original cage until the second trial (recovery), during which they were free to explore the three arms of the maze for 5 minutes.
  • Total residence time (exploration) in each arm was measured and analyzed from video recordings.
  • the entrance to the arm was defined as the entrance of the four legs of the animal on said arm.
  • the time spent (sec) in each arm during the learned task retrieval test was used for statistical analysis.
  • the maze was cleaned with 70% ethanol between trials. All mice were transported to the behavioral testing room in their home cages at least 1 day prior to testing. The experiments were carried out between 8:00 am and 12:30 pm.
  • mice were transported to the behavioral testing room in their home cages at least 1 day prior to testing and experiments were performed between 8:00 am and 12:30 pm.
  • the animals were trained according to the criterion in a series of visible platform tests on day 1 (D1) in a pool of 120 cm in diameter and 51 cm in depth with the water temperature of 24 ⁇ 2 °C, in which they placed high-contrast visual cues on the wall in each quadrant and external cues in the room.
  • D1V4 day 1, visible test platform 4
  • the D2T1-D1V4 score for a successful subject should be close to 0, and the D2T1/D1V4 score around 1 or less. Higher values indicate a longer escape latency after 24 h, implying a deficit in the animals' spatial performance. This comparison was performed using a one-way analysis of variance, followed by Turkey's post-hoc test. Data analysis of the Y-maze was also performed using the same test as above. A p ⁇ 0.05 was considered as a statistically significant difference. Statistical analysis was performed using GraphPadPrism version 5 (GraphPad Software, Inc, San Diego, USA, ULL).
  • Example 3 Evaluation of the anticholinergic modulatory effect of the compound methyl (2- ⁇ [4-(1-naphthylamino)-4-oxobutanoyl]amlno ⁇ ethyl)dithio carbamate (3) in a model of memory loss induced with the acute use of Scopolamine via AChE activity in whole brain homogenates.
  • the absorbance of the yellow hydrolyzate of the 5-thio-2-nitrobenzoic acid dianion was measured at 412 nm, for 20 minutes with an interval of 1 minute.
  • AChE activity was performed in triplicate and expressed in nmol of Ach ⁇ hydrolyzed per minute per mg of protein. Protein concentrations were determined by the modified Lowry method (Markwell MAK et al. in Anal. Biochem. 1978, 87(1): 206-210).
  • Example 4 Evaluation of the anticholinergic modulating effect of the compound methyl (2- ⁇ [4-(1-naphthylamino)-4-oxobutanoyl]amlno ⁇ ethyl)dithio carbamate (3) in a model of memory loss induced with the chronic use of Scopolamine.
  • mice Male C57BL/6 mice (20-25 g) supplied by the National Center for the Production of Laboratory Animals (CENPALAB, Cuba) were used. During the experiment, the animals received ad libitum water and a standard diet supplied by CENPALAB. All procedures were carried out in accordance with the European Commission guidelines for the use and care of laboratory animals and approved by the Committee for the Care of Animals in Research. The minimum number of animals and duration of observations required to obtain consistent data were used.
  • the animals were randomly distributed according to their body weights in five experimental groups of 12 animals each.
  • ESC Sigma Aldrich
  • Compound 3 was prepared as a suspension, in 0.5% soluble starch (Merck Millipore), and administered orally by intragastric cannula at a daily dose of 0.1, 1, 10 mg/kg of body weight (0.01 mL/kg).
  • the experimental groups were:
  • Group 1 negative control with normal cognitive function.
  • Group 2 (positive control) with cognitive dysfunction. Daily administrations of ESC 1.5 mg/kg for two weeks and vehicle (starch 0.5% orally).
  • IMWM Morris Water Maze
  • Example 5 Neuroprotective effect of the methyl compound (2- ⁇ [4-(1-naphthylamino)- 4-oxobutanoyl]amlno)ethyl)dithio carbamate (3) on glutamate-induced exclitotoxic damage in the SH-SY5Y cell line.
  • Compound 3 was dissolved in DMSO at a concentration of 100 mmol/L, and subsequently distributed in aliquots and stored at -20 °C.
  • RPMI 1640 (1X) + GlutaMax medium Gibco Laboratories Life Technologies, Inc.; Rockville, MD, USA
  • HEPES buffer 25 mmol/L
  • L-glutamine 2 mmol/L
  • FBS Fetal Bovine Serum
  • 1% sodium pyruvate 100 mmol/L
  • antibiotic mixture penicillin 10,000 U/mL
  • gentamicin 10 mg/mL
  • Trypsin-EDTA 0.25%
  • phosphate buffered saline DPBS 1X
  • SH-SY5Y human neuroblastoma cells were grown in T-75 cm 2 flasks with RPMI 1640 culture medium containing HEPES buffer (25 mmol/L) and L-glutamine (2 mmol/L). L) supplemented with 10% fetal bovine serum (FBS), previously inactivated by heat, sodium pyruvate 1 mmol/L, mixture of benzylpenicillin (100 U/mL) and streptomycin (100 pg/mL) antibiotics. In addition, gentamicin (100 pg/mL) was added, thus being called complete medium (MC).
  • FBS fetal bovine serum
  • gentamicin 100 pg/mL was added, thus being called complete medium (MC).
  • the culture was incubated in a humid atmosphere of 5% CO 2 , 95% air and a temperature of 37 °C.
  • the medium was changed every two days and the cells were subcultured every five days by trypsinization at a density of 4-5 x 10 6 cells/75 cm 2 flask for experimental work and/or subculture of a new generation of cells for later use.
  • cytotoxicity SH-SY5Y human neuroblastoma cells were cultured in RPM1 1640 (MC) incubated at 37 °C in an atmosphere of 5% CO 2 and 95% air. When they reached a confluence between 80-90%, they are trypsinized with a mixture of Trypsin/EDTA 0.25% (1 mL/25 cm 2 ) for 2-3 minutes to detach the cells. Then this suspension is neutralized with an equal volume of MC. Subsequently, they were centrifuged at 112 XG for 8 minutes, the supernatant was removed by decanting, and the precipitate was resuspended in 1 mL of complete medium for counting in the hemocytometer.
  • cell density was known, they were seeded in 96-well culture plates (200 ⁇ L in each well) at a concentration of 80 x 10 4 cells/well, after 24 hours of incubation, 100 ⁇ L of supernatant were removed from each well and subsequently add 100 ⁇ L of compound 3, prepared in MC at different concentrations (0.93; 1.87; 3.75; 7.5; 15; 30; 60 and 100 ⁇ mol/L) and incubated again for 24 hours under conditions of CO 2 5%, air 95% at 37°C. After the incubation time, cell viability was determined by the MTT assay.
  • Neuroprotection of methyl (2- ⁇ [4-(1-naphthylamino)-4-oxobutanoylamino ⁇ ethyl)dithio carbamate against olutamate-induced neuronal death To evaluate the neuroprotective effect of compound 3, the cell line SH- SY5Y until reaching a confluency between 80-90%, the cells were trypsinized and subsequently counted in the hemocytometer. Once the cell density was known, they were seeded in a 96-well culture plate (200 ⁇ L in each well) at a concentration of 80 x 10 4 cells/well.
  • MTT assays Cell viability was measured through the blue formazan products obtained from the enzymatic transformation of MTT (from English: “3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2Htetrazoliumbromide” ) by mitochondrial dehydrogenases, which are active only in viable cells. The assay was performed in 96-well plates, the cells were exposed to glutamate as a stressing agent, to compound 3 or to both at different times and concentrations. After being subjected to the different treatments, MTT (freshly prepared at 5 mg/mL in MC) was added at 50 ⁇ L/well and incubated for 4 hours in an atmosphere of CO 2 5%, air 95% at 37° c.
  • Example 6 Neuroprotective effect of the methyl compound (2- ⁇ [4-(1-naphthylamino)-4-oxobutanoyl]amlno ⁇ ethyl)dithio carbamate (3) on convulsions induced by the lev administration of kainic acid.
  • mice Young male OF-1 mice (20-25 g) supplied by the National Center for the Production of Laboratory Animals (CENPALAB, Cuba) were used. The adaptation and maintenance conditions of the animals before carrying out the experiment were similar to those developed in non-limiting Example 2.
  • the mice were divided into 5 experimental groups (7 animals/group) distributed in: a control group (PBS 2 ⁇ L icv), a seizure control group (AK 2 ⁇ L, icv) and three groups treated orally by gastric cannulation with compound 3 at doses of 1, 5, 50 mg/kg (0.01 mL/kg) and AK 2 ⁇ L, icv.
  • Compound 3 was prepared as a suspension in vehicle 5% carboxymethylcellulose (CMC). The administration of 3 and of the vehicle in the control groups was carried out 1 h before the icv injection of AK. All animals were administered AK (Sigma Aldrich) prepared in PBS at a concentration of 0.5 mg/mL.
  • mice were anesthetized with 685.71 mg/kg doral hydrate i.p. and placed in a dual manipulator. The stereotaxic frame and skull were exposed. Stereotaxic coordinates for the lateral ventricle were precisely measured as: anteroposterior -0.8 mmol/L, lateral ⁇ 1.0 mmol/L, and dorsoventral -3.0 mmol/L relative to bregma and ventral to dura with the tooth bar at 0 mmol/L. . A burr hole was made in the skull by automated micro-drilling attached to an arm of the stereotaxic apparatus.
  • a 10 ⁇ L 28-gauge Hamilton® syringe was placed through the orifice, attached to another arm of the stereotaxic apparatus, and the syringe piston was manually lowered into the right lateral ventricle, emptying its contents for 3 minutes.
  • Seizure scoring was performed according to the Racine scale (R.J. Racine, in Clin. Neurophysiol. 1972, 32281-294) using the following measurement criteria: (1) immobility, mouth and face movements; (2) forelimb extension and/or tail extension, rigid posture; (3) repetitive movements, head rocking; (4) steepness and drop; (5) continuous steepness and drops; (6) severe tonic-clonic seizures; (7) death.
  • Each animal was observed by two independent observers and behaviors were quantified for 2 hours. The sum of the score accumulated by each animal during this time interval was used for statistical analysis.
  • Example 7 Formula 1 for the manufacture of tablets with hydroxypropylmethylcellulose (HPMC) of the active ingredients N-[4-(1-naphthylamino)-4-oxobutanoyl]- ⁇ -alanine (1) and methyl (2- ⁇ [4-( 1-naphthylamino)-4-oxobutanoyl]amlno ⁇ ethyl)dithio carbamate (3).
  • HPMC hydroxypropylmethylcellulose
  • the tablets obtained were smooth and uniform, the weight variation is less than 1%, of adequate hardness (4.51 ⁇ 0.37 kgf), with good resistance to abrasion, adequate disintegration time and the content of the active ingredient is was between 90 and 110%.
  • Example 8 Formula 2 for the manufacture of tablets with hydroxypropylcellulose (HPC) of the active ingredients N-[4-(1-naphthylamino)-4- oxobutanoyl]- ⁇ -alanine (1) and methyl (2- ⁇ [4-(1-naphthylamino)-4-oxobutanoyl]amno ⁇ ethyl)dithio carbamate (3).
  • HPC hydroxypropylcellulose
  • the tablets obtained were smooth and uniform, the weight variation is less than 1%, of adequate hardness (4.51 ⁇ 0.37 kgf), with good resistance to abrasion, adequate disintegration time and the content of the active ingredient is was between 90 and 110%.
  • Example 9 Formula 3 for the manufacture of tablets with EUDRAGIT and lactose of the active ingredient methyl (2- ⁇ [4-(1-naphthylamino)-4-oxobutanoyl]amino ⁇ ethyl)dithio carbamate (3).
  • the tablets obtained were smooth and uniform, the variation in weight is less than 1%, adequate hardness (5.01 ⁇ 0.68 kgf), good resistance to abrasion, adequate disintegration time and the content of the active ingredient was between 90 and 110%
  • Solution A Compound 3 is solubilized in PEG 400, Tocopherol and glycerol.
  • Solution B The HPMC is resuspended in 40% of the water, until completely dissolved with stirring and heat (80 °C).
  • Solution C Benzalkonium chloride, NaH 2 PO 4 , Na 2 HPO 4 , NaCl, EDTA, and Tween 80 are dissolved in 60% water. It is verified that the pH remains at 6.3.
  • Solutions B and C are then combined and stirred until a homogeneous solution is obtained. Then, solution A is slowly added to this solution, stirring, and finally, it is filtered through a 0.2 ⁇ mol/L membrane.
  • Example 11 Nasal formulation of 1 (N-[4-(1-naphthylamino)-4-oxobutanoyl]- ⁇ -alanine (1)
  • Solution A Compound 3 is solubilized in PEG 400, Tocopherol and glycerol.
  • Solution B The HPMC is resuspended in 40% of the water, until completely dissolved with stirring and heat (80 °C).
  • Solution C Benzalkonium chloride, NaH 2 PO 4 , Na 2 HPO 4 , NaCl, EDTA, and Tween 80 are dissolved in 60% water. It is verified that the pH remains at 6.3.
  • Solutions B and C are then combined and stirred until a homogeneous solution is obtained. Then, solution A is slowly added to this solution, stirring, and finally, it is filtered through a 0.2 ⁇ mol/L membrane.
  • Each tablet was placed in the dissolution apparatus (Distek, model Evolution 6100) with 600 mL of dissolution medium-1 at 37° ⁇ 0.5 °C, stirred at 30 rpm for 60 minutes. A portion of the medium under test was filtered immediately through a 0.45 ⁇ mol/L filter, at 5, 15, 30 and 60 minutes of testing.
  • dissolution medium-1 was drained from the dissolution apparatus and replaced by 600 mL of dissolution medium-2 at a temperature of 37° ⁇ 0.5 °C, stirring at 30 rpm for an additional 8 hours.
  • the absorbances of the sample solutions in each dissolution medium were obtained at the length of maximum absorbance determined.
  • a UV-Vis ( ⁇ max ) spectrophotometric calibration curve was made, in the concentration range of 0.025 to 0.150 mg/mL and an adjustment blank (dissolution medium) was used.
  • the methodology used complies with the parameters of linearity (R>0.999), precision (reproducibility and repeatability) and accuracy required of an analytical methodology, allowing precise and exact results to be obtained within the range of concentrations and in the experimental conditions used in this study
  • Example 13 Evaluation of the anticholinergic modulating effect of the compound methyl (2- ⁇ [4-(1-naphthylamino)-4-oxobutanoyl]amlno ⁇ ethyl)dithio carbamate (3) administered nasally (Formulation according to Example 10) in a model of memory loss induced by chronic use of scopolamine
  • mice Male C57BL/6 mice (20-25 g) supplied by the National Center for the Production of Laboratory Animals (CENPALAB, Cuba) were used. The adaptation and maintenance conditions for the animals before carrying out the experiment were similar to those developed in non-limiting Example 4. Experimental design.
  • the animals were randomly distributed according to their body weights into four experimental groups of 10 animals each: two healthy control groups, one administered with vehicle through the nasal route (G1) and the other with saline solution through the nasal route. i.p. (G2); a sick control group, administered with nasal saline and then with ESC dissolved in saline (1.5 mg/kg, i.p.) (G3) and a treated group, administered with compound 3 prepared according to the formulation of non-limiting Example 10 and after 15 minutes, ESC (1.5 mg/kg, i.p.) is administered (G4).
  • This experiment was carried out in two experimental series under the same conditions described in order to study the effects of the nasal formulation of compound 3 in two behavioral models: Y-maze in the hidden arm modality and the object discrimination model. In this way, a total of 60 animals were used.
  • the mouse was placed in its cage and after two minutes, another application was made in both nostrils.
  • the animal was immobilized three times and a total volume of 30 ⁇ L was applied, equivalent to a dose of compound 3 of 7.2 mg/kg of weight.
  • 15 minutes after the last administration each animal was administered ip 1.5 mg/kg of ESC. or its vehicle (saline solution) and after 30 minutes the behavioral experiments were performed.
  • the Object Recognition Test is a behavioral assay commonly used for the investigation of various aspects of learning and memory, particularly recognition memory, in rodent models of CNS disorders.
  • the protocol used consists of three phases: a first phase of habituation (day 1), a second phase of familiarization (day 2) and finally the test phase (day 3). All phases lasted five minutes and were performed on three consecutive days.
  • the animals were placed in a Plexiglas box (25 cm x 25 cm x 25 cm) inside. The behavior of the animal was recorded using a video camera. This first day the animals were taken to the testing room 30 minutes before the experiment to familiarize themselves with the environment. The mice were then allowed to freely explore the box in the absence of objects for five minutes.
  • each mouse underwent the training test in which two identical objects were placed in two opposite positions inside the box at the same time. same distance from the nearest corner. During this phase the mice were allowed to explore the identical objects for five minutes and then returned to their home cages. During the test phase (day 3) the animals were placed back in the same box, where one of the two familiar objects was exchanged for a new one, before this phase. All the objects used in this study were different in shapes and colors but identical in size. They were fixed to the floor of the box to prevent movement. To avoid the existence of olfactory signals, the entire box and the objects were always cleaned with 70% alcohol after each test. The ability to discriminate the new from the familiar object was observed through the time needed to explore the objects.
  • the object exploration time was defined as the period of time during which the animal directed its nose to a distance of 2 cm from the object, or sniffed or pawed at it. Sitting or standing on the object was not recognized as exploration. Scan time was manually analyzed using intelligent video software.
  • the discrimination index (DI) was calculated as follows.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PCT/CU2021/050012 2020-11-24 2021-11-18 Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer Ceased WO2022111742A1 (es)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA3200071A CA3200071A1 (en) 2020-11-24 2021-11-18 Pharmaceutical composition of naphthalene derivatives as multi-target therapeutic agents for the treatment of alzheimer's disease
US18/038,494 US20240299334A1 (en) 2020-11-24 2021-11-18 Pharmaceutical composition of naphthalene derivatives as multi-targeted therapeutic agents for the treatment of alzheimer's disease
AU2021388673A AU2021388673A1 (en) 2020-11-24 2021-11-18 Pharmaceutical composition of naphthalene derivatives as multi-target therapeutic agents for the treatment of alzheimer's disease
KR1020237020732A KR20230118112A (ko) 2020-11-24 2021-11-18 알츠하이머병의 치료를 위한 다중 표적 치료제로서 나프탈렌 유도체의 약학적 조성물
CN202180091389.3A CN116829137A (zh) 2020-11-24 2021-11-18 用于治疗阿尔茨海默氏病的作为多靶标治疗剂的萘衍生物的药物组合物
MX2023006072A MX2023006072A (es) 2020-11-24 2021-11-18 Composicion farmaceutica de derivados de naftaleno como agentes terapeuticos multiblancos para el tratamiento de la enfermedad de alzheimer.
JP2023531700A JP2023551249A (ja) 2020-11-24 2021-11-18 アルツハイマー病の治療のためのマルチターゲット治療薬としてのナフタレン誘導体の医薬組成物
EP21848149.7A EP4252749A1 (en) 2020-11-24 2021-11-18 Pharmaceutical composition of naphthalene derivatives as multi-target therapeutic agents for the treatment of alzheimer's disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU2020000087A CU24720B1 (es) 2020-11-24 2020-11-24 Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer
CU2020-0087 2020-11-24

Publications (2)

Publication Number Publication Date
WO2022111742A1 true WO2022111742A1 (es) 2022-06-02
WO2022111742A4 WO2022111742A4 (es) 2022-11-03

Family

ID=80034851

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CU2021/050012 Ceased WO2022111742A1 (es) 2020-11-24 2021-11-18 Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer

Country Status (10)

Country Link
US (1) US20240299334A1 (cg-RX-API-DMAC7.html)
EP (1) EP4252749A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023551249A (cg-RX-API-DMAC7.html)
KR (1) KR20230118112A (cg-RX-API-DMAC7.html)
CN (1) CN116829137A (cg-RX-API-DMAC7.html)
AU (1) AU2021388673A1 (cg-RX-API-DMAC7.html)
CA (1) CA3200071A1 (cg-RX-API-DMAC7.html)
CU (1) CU24720B1 (cg-RX-API-DMAC7.html)
MX (1) MX2023006072A (cg-RX-API-DMAC7.html)
WO (1) WO2022111742A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119523898A (zh) * 2024-12-02 2025-02-28 肇庆学院 多靶点药物的经鼻给药制剂及其应用

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5382601A (en) 1992-08-04 1995-01-17 Merz + Co. Gmbh & Co. Memantine-containing solid pharmaceutical dosage forms having an extended two-stage release profile and production thereof
US20030225031A1 (en) 2002-05-21 2003-12-04 Quay Steven C. Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid
CN1621039A (zh) 2003-11-25 2005-06-01 上海医药工业研究院 石杉碱甲及其衍生物或其盐的经鼻脑靶向制剂
US20050245617A1 (en) 2004-01-29 2005-11-03 Meyerson Laurence R Methods and compositions for the treatment of CNS-related conditions
US20060003989A1 (en) 2002-05-21 2006-01-05 Nastech Pharmaceutical Company Inc. Compositions and methods using acetylcholinesterase (ACE) inhibitors to treat central nervous system (CNS) disorders in mammals
US20060051416A1 (en) 2004-06-17 2006-03-09 Forest Laboratories, Inc. Modified release formulations of memantine oral dosage forms
US20060189694A1 (en) 2004-11-24 2006-08-24 Went Gregory T Composition and method for treating neurological disease
US20060252788A1 (en) 2005-04-06 2006-11-09 Went Gregory T Methods and compositions for the treatment of CNS-related conditions
US20070037800A1 (en) 2005-06-23 2007-02-15 Envivo Pharmaceuticals, Inc. Method of treating neurological disorders using clotrimazole and derivatives thereof
WO2010118706A2 (es) 2009-04-17 2010-10-21 Centro De Neurociencias De Cuba Procedimiento de obtención de nuevos derivados de naftaleno para el diagnóstico in vivo de la enfermedad de alzheimer
WO2014131374A1 (es) 2013-02-28 2014-09-04 Centro De Neurociencias De Cuba (Neuronic) Chaperoninas químicas como nuevos moduladores moleculares de la beta agregación proteica presente en las enfermedades conformacionales
WO2020094161A1 (es) * 2018-11-06 2020-05-14 Centro De Neurociencias De Cuba Nanopartículas de óxidos metálicos conjugados con derivados de naftaleno en cuanto agentes de contraste para la detección de placas beta amiloides por imágenes de resonancia magnética

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070141148A1 (en) * 2005-11-30 2007-06-21 Merz Pharma Gmbh & Co. Kgaa Neramexane MR matrix tablet
US7745670B2 (en) * 2008-06-27 2010-06-29 Codman & Shurtleff, Inc. Curcumin-Resveratrol hybrid molecule

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5382601A (en) 1992-08-04 1995-01-17 Merz + Co. Gmbh & Co. Memantine-containing solid pharmaceutical dosage forms having an extended two-stage release profile and production thereof
US20030225031A1 (en) 2002-05-21 2003-12-04 Quay Steven C. Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid
US20060003989A1 (en) 2002-05-21 2006-01-05 Nastech Pharmaceutical Company Inc. Compositions and methods using acetylcholinesterase (ACE) inhibitors to treat central nervous system (CNS) disorders in mammals
CN1621039A (zh) 2003-11-25 2005-06-01 上海医药工业研究院 石杉碱甲及其衍生物或其盐的经鼻脑靶向制剂
US20050245617A1 (en) 2004-01-29 2005-11-03 Meyerson Laurence R Methods and compositions for the treatment of CNS-related conditions
US20060051416A1 (en) 2004-06-17 2006-03-09 Forest Laboratories, Inc. Modified release formulations of memantine oral dosage forms
US20060189694A1 (en) 2004-11-24 2006-08-24 Went Gregory T Composition and method for treating neurological disease
US20060252788A1 (en) 2005-04-06 2006-11-09 Went Gregory T Methods and compositions for the treatment of CNS-related conditions
US20070037800A1 (en) 2005-06-23 2007-02-15 Envivo Pharmaceuticals, Inc. Method of treating neurological disorders using clotrimazole and derivatives thereof
WO2010118706A2 (es) 2009-04-17 2010-10-21 Centro De Neurociencias De Cuba Procedimiento de obtención de nuevos derivados de naftaleno para el diagnóstico in vivo de la enfermedad de alzheimer
WO2014131374A1 (es) 2013-02-28 2014-09-04 Centro De Neurociencias De Cuba (Neuronic) Chaperoninas químicas como nuevos moduladores moleculares de la beta agregación proteica presente en las enfermedades conformacionales
US20160106691A1 (en) * 2013-02-28 2016-04-21 Centro De Neurociencias De Cuba (Neuronic) Chemical chaperonins as novel molecular modulators of beta protein aggregation present in conformational diseases
WO2020094161A1 (es) * 2018-11-06 2020-05-14 Centro De Neurociencias De Cuba Nanopartículas de óxidos metálicos conjugados con derivados de naftaleno en cuanto agentes de contraste para la detección de placas beta amiloides por imágenes de resonancia magnética
EP3878475A1 (en) * 2018-11-06 2021-09-15 Centro De Neurociencias De Cuba Metal oxides nanoparticles conjugated with naphthalene derivatives as contrast agents for the detection of beta amyloid plaques by magnetic resonance images

Non-Patent Citations (106)

* Cited by examiner, † Cited by third party
Title
AISEN PS ET AL., ARCH MED SCI, vol. 7, 2011, pages 102 - 11
ALEARDI, A. M. ET AL., J. BIOENERG. BIOMEMBR., vol. 37, 2005, pages 207 - 225
ALI T ET AL., PLOS ONE, vol. 7, 2015, pages 1 - 10
BATEMAN, R. J. ET AL.: "Alzheimer's disease", N. ENGL. J. MED., vol. 367, 2012, pages 795 - 804
BEHL CR ET AL., EN ADV DRUG DEL REV, vol. 29, no. 1, 1998, pages 89 - 116
BIHAQI SW ET AL., INDIAN J. PHARMACOL., vol. 44, no. 5, 2012, pages 593 - 598
BRORSON, J.R. ET AL., J. NEUROSCI., vol. 14, no. 1, 1994, pages 187 - 197
CALTAGIRONE C ET AL., ALZHEIMERS DIS, vol. 20, 2010, pages 509 - 16
CASETTARI, LLIIUM, L, J. CONTROL. RELEASE, vol. 190, 2014, pages 189 - 200
CASLEY ET AL., NEUROBIOL. DIS., vol. 10, 2002, pages 258 - 267
CASPERSEN, C ET AL., FASEB J, vol. 19, 2005, pages 2040 - 2041
CASTELLO MA ET AL., AGEING RES REV, vol. 12, 2013, pages 282 - 8
CASTELLO MA ET AL., AGEING RES REV, vol. 13, 2014, pages 10 - 2
CHEN, Z. ET AL., J. NEUROBIOL., vol. 62, no. 2, 2005, pages 207 - 218
CHIANG K ET AL., ANNU REV PHARMACOL TOXICOL, vol. 54, 2014, pages 381 - 405
CLEMENTI, M. E. ET AL., FEBS LETT, vol. 579, 2005, pages 2913 - 2918
COCHRAN JN ET AL., BRAIN RES BULL, vol. 103, 2014, pages 18 - 28
CSISZAR A. ET AL., AM. J. PHYSIOL. HEART CIRC. PHYSIOL., vol. 305, 2013, pages H1120 - 1130
DABBAGH, M.A. ET AL., INTERNACIONAL. JOURNAL OF PHARMACEUTICS, vol. 140, 1996, pages 85 - 95
DE BRUIN N ET AL., J NEURODEGENER DIS, vol. 2015, 2015, pages 242505
DE FELICE FG ET AL., DIABETES, vol. 63, 2014, pages 2262 - 72
DE FELICE FG, J CLIN INVEST, vol. 123, 2013, pages 531 - 9
ELALI A ET AL., BRAIN, BEHAVIOR, AND IMMUNITY, 2015
ELLMAN GL ET AL., BIOCHEM PHARMACOL., vol. 7, 1961, pages 88 - 95
FERREIRA ST ET AL., ALZHEIMERS DEMENT, vol. 10, 2014, pages S76 - 83
FRANCIS PT ET AL., TRENDS PHARMACOL SCI, vol. 26, 2005, pages 104 - 11
FRENKEL, J., RUBBER CHEMISTRY AND TECHNOLOGY, vol. 13, 1940, pages 264 - 274
FREY WH II, DRUG DELIV TECH, vol. 2, 2002, pages 46 - 49
FROLICH L ET AL., J ALZHEIMERS DIS, vol. 24, 2011, pages 363 - 74
FYFE, C.A.BLAZER, A.I., JOURNAL OF CONTROLLED RELEASE, vol. 52, 1998, pages 221 - 225
GILLES CERTLE S, DIALOGUES CLIN. NEUROSCI., vol. 2, no. 3, 2000, pages 247 - 255
GULINELLO M.,M. GERTNER ET AL., BEHAV. BRAIN RES., vol. 196, no. 1, 2009, pages 220 - 227
HAASS C ET AL., COLD SPRING HARB PERSPECT MED., vol. 2, 2012, pages a006270
HAIDER ET AL., BRAIN RESEARCH BULLETIN, vol. 127, 2016, pages 234 - 247
HAIDER S ET AL., BRAIN RES. BULL., vol. 127, 2016, pages 234 - 247
HAIDER, S ET AL., BRAIN RESEARCH BULLETIN, vol. 127, 2016, pages 234 - 247
HANSON, L.R. ET AL., J. VIS. EXP., no. 74, 2013, pages e4440 - 3221
HARDY JA ET AL., SCIENCE, vol. 256, 1992, pages 184 - 5
HUANG Y ET AL.: "148", CELL, vol. 148, 2012, pages 1204 - 22
INTILOIU, A.LEROUX,J.C.: "Organogels and their use in drug delivery", JOURNAL OF CONTROLLED RELEASE, vol. 125, 2008, pages 179 - 192, XP022432121, DOI: 10.1016/j.jconrel.2007.09.014
JUNG ET AL., BIOL. PHARM. BULL., vol. 32, no. 2, 2009, pages 242 - 246
JÜRGENSMEIER, J. M. ET AL., PROC. NATI. ACAD. SCI. USA, vol. 95, 1998, pages 14681 - 14686
KARRAN, E. ET AL., NAT. REV. DRUG DISCOV., vol. 10, 2011, pages 698 - 712
KLINKENBERG IBLOKLAND A, NEUROSCI BIOBEHAV REV, vol. 34, no. 8, 2010, pages 1307 - 1350
KONAR ET AL., PLOS ONE, vol. 6, no. 11, 2011, pages e27265
KROEMER, G.REED, J. C., NAT. MED., vol. 6, 2000, pages 513 - 519
LEE J-S ET AL., SCIENTIFIC REPORTS, vol. 5, 2015, pages 9651
LEUNER ET AL., MOL. NEUROBIOL., vol. 46, 2012, pages 186 - 193
LIIUM L, EUR J PHARM SCI, vol. 11, 2000, pages 1 - 18
LIU, X. ET AL., CELL, vol. 86, 1996, pages 147 - 157
LUSTBADER ET AL., SCIENCE, vol. 304, 2004, pages 448 - 452
MALM T. M.,, NEUROTHERAPEUTICS, vol. 12, 2015, pages 81 - 93
MANCZAK ET AL., HUM. MOL. GENET., vol. 15, 2006, pages 1437 - 1449
MANSURI, S ET AL., REACT. FUNCT. POLYM., vol. 100, 2016, pages 151 - 172
MARKWELL MAK ET AL., ANAL. BIOCHEM., vol. 87, no. 1, 1978, pages 206 - 210
MARZO, I. ET AL., SCIENCE, vol. 281, 1998, pages 2027 - 2031
MAURER, L. ET AL., NEUROBIOL. AGING, vol. 21, 2000, pages 455 - 462
MCGAUGH J.L, SCIENCE, vol. 153, 1966, pages 1351
MICHAEL IU ET AL., J PHARM PHARMACOL, vol. 53, 2001, pages 3 - 22
MICHAUD J.-P. ET AL., NEURON, vol. 85, no. 4, 2015, pages 450 - 2
MIRANDA HF ET AL., J. BIOMED. SCI., vol. 21, no. 1, 2014, pages 62 - 62
MIRANDOLA SR ET AL., J NEUROSCI RES, vol. 88, 2010, pages 630 - 39
MORRIS R, JOURNAL OF NEUROSCIENCE METHODS, vol. 11, no. 1, 1984, pages 47 - 6
MOSCONI, L ET AL., ANN. N Y ACAD. SCI., vol. 1147, 2008, pages 180 - 195
MUCKE L ET AL., COLD SPRING HARB PERSPECT MED, vol. 2, 2012, pages a006338
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE: "Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease", TECHNOLOGY APPRAISAL GUIDANCE 217
O'BRÍEN JT ET AL., J PSYCHOPHARMACOL OXF ENGL, vol. 25, 2011, pages 997 - 1019
OLTON D.S.PARAS B.C., NEUROPSYCHOLOGIA, vol. 17, 1979, pages 669 - 682
OSTROWITZKI S ET AL., ARCH NEUROL, vol. 69, 2012, pages 198 - 207
OYON HONG ET AL., SCIENCE, 2016
PANZA F ET AL., EXPERT REV CLIN IMMUNOL, vol. 10, 2014, pages 405 - 19
PARK JH ET AL., J MOL NEUROSCI, vol. 59, no. 4, 2016, pages 579 - 589
PIRES, A ET AL., J PHARM. PHARMACEUT SCI., vol. 12, no. 3, 2009, pages 288 - 311
R.J. RACINE, CLIN. NEUROPHYSIOL., vol. 32, 1972, pages 281 - 294
RAMANDEEP K ET AL., INT J PREV MED RES, vol. 1, no. 2, 2015, pages 45 - 64
REITZ C, INTERNATIONAL JOURNAL OF ALZHEIMER'S DISEASE, vol. 2012, January 2012 (2012-01-01), pages 369808
RIVERA-MARRERO SUCHITIL ET AL: "A new naphthalene derivative with anti-amyloidogenic activity as potential therapeutic agent for Alzheimer's disease", BIOORGANIC, ELSEVIER, AMSTERDAM, NL, vol. 28, no. 20, 11 August 2020 (2020-08-11), XP086296996, ISSN: 0968-0896, [retrieved on 20200811], DOI: 10.1016/J.BMC.2020.115700 *
RODRIGUE K, NEUROPSYCHOL REV, vol. 19, no. 4, December 2009 (2009-12-01), pages 436 - 450
RODRIGUEZ, I.C.CEREZO, A.SALEM, EN /./.: "Bioadhesive delivery systems", ARS PHARMACEUTICA, vol. 41, no. 1, 2000, pages 115 - 128
RYAN R. JM ET AL., J ALZHEIMERS DIS, vol. 17, 2009, pages 243
SALLOWAY S ET AL., NEUROLOGY, vol. 77, 2011, pages 1253 - 62
SCHNEEBERGER A ET AL., N ENGL J MED, vol. 370, 2014, pages 322 - 33
SHIN CY ET AL., BIOMOLECULES & THERAPEUTICS, vol. 26, no. 3, 2018, pages 274 - 281
SMITH, M. A. ET AL., NATURE, vol. 382, 1996, pages 120 - 121
TANAKA ET AL.: "Encyclopedia of Polymer Science", vol. 6, 1986, pages: 514
THOMSON PDR ET AL., CLINICAL GERIATRICS, vol. 2011, no. 19, pages 1
THORNE RG ET AL., NEUROSCIENCE, vol. 127, 2004, pages 481 - 496
THORNE, R.G. ET AL., NEUROSCIENCE, vol. 127, 2002, pages 481 - 496
TSOI K. K. F., JAMDA, 2015, pages 1 - 7
UEDA, Y ET AL., EXP. BRAIN RES., vol. 147, no. 2, 2002, pages 219 - 226
VELLAS B, CURR ALZHEIMER RES, vol. 8, 2011, pages 203 - 12
VILLEGAS S, MEDICINA CLÍNICA, vol. 145, no. 2, 2015, pages 76 - 83
VOTYAKOVAREYNOLDS, J NEUROCHEM, vol. 79, no. 2, 2001, pages 266 - 77
VYAS TK ET AL., CURR DRUG DELIV, vol. 2, no. 2, 2005, pages 164 - 175
WANG Q ET AL., MOL NEUROBIOL, vol. 31, 2005, pages 3 - 16
WANG, Q ET AL., MOL. NEUROBIOL., vol. 31, no. 1-3, 2005, pages 3 - 16
WINBLAD B ET AL., LANCET NEUROL, vol. 11, 2012, pages 597 - 604
WONG WB ET AL., PHARMACOEPIDEMIOL DRUG SAF, vol. 22, 2013, pages 345 - 58
WONG-GUERRA ET AL., NEUROL RES, vol. 39, no. 7, 2017, pages 649 - 659
XIA W, J ALZHEIMERS DIS, vol. 31, 2012, pages 685 - 96
YAN R ET AL., LANCET NEUROL, vol. 13, 2014, pages 319 - 29
YANG, J. ET AL., SCIENCE, vol. 275, 1997, pages 1129 - 1132
YATES ET AL., J. NEUROCHEM, vol. 55, 1990, pages 1624 - 1630
ZÁDORI D, JOURNAL OF ALZHEIMER'S DISEASE, vol. 62, 2018, pages 523 - 547
ZANOTTI A.AZZONE G.F., ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 201, no. 1, 1980, pages 255 - 265
ZAWIEJA P ET AL., GERIATR GERONTOL. INT., vol. 12, 2012, pages 365 - 71

Also Published As

Publication number Publication date
JP2023551249A (ja) 2023-12-07
KR20230118112A (ko) 2023-08-10
EP4252749A1 (en) 2023-10-04
AU2021388673A1 (en) 2024-03-28
CN116829137A (zh) 2023-09-29
US20240299334A1 (en) 2024-09-12
CU20200087A7 (es) 2022-07-08
WO2022111742A4 (es) 2022-11-03
CA3200071A1 (en) 2022-06-02
MX2023006072A (es) 2023-06-29
CU24720B1 (es) 2024-10-09

Similar Documents

Publication Publication Date Title
JP6250588B2 (ja) L−オルニチンフェニル酢酸塩を用いる門脈圧亢進の治療及び肝機能の修復
ES2370943T3 (es) Composiciones farmacéuticas estabilizadas que comprenden fesoterodina.
ES2606050T3 (es) Composición farmacéutica que comprende linagliptina y un inhibidor de sglt2, y usos de la misma
Millotti et al. In vivo evaluation of thiolated chitosan tablets for oral insulin delivery
KR100699958B1 (ko) 테르비나핀을 포함하는 제약학적 조성물 및 그의 용도
AU2015326392B2 (en) Pharmaceutical compositions comprising alpelisib
CN116367837A (zh) 抗病毒化合物的制剂
KR20190083369A (ko) 약물 전달 시스템
US20110301243A1 (en) Novel method
EP4252749A1 (en) Pharmaceutical composition of naphthalene derivatives as multi-target therapeutic agents for the treatment of alzheimer's disease
PT1807156T (pt) Novas formulações farmacêuticas úteis no tratamento de insónia
CA2754089A1 (en) Pharmaceutical composition containing 1h-inden-1-amine, 2,3-dihydro-n-2-propynyl-, (1r)-, methanesulfonate
ES2402865T3 (es) Formulación farmacéutica que contiene fluvastatina
HK40092074A (en) Pharmaceutical composition of naphthalene derivatives as multi-target therapeutic agents for the treatment of alzheimer's disease
ES2383149T3 (es) Composicion farmacéutica estable para la administración optimizada de un inhibidor de la unión del VIH
RU2593570C1 (ru) Противовирусное и иммуностимулирующее лекарственное средство
Thulsiram et al. Characterization and evaluation of pantoprazole oral matrix tablets with silica-based polymer material
HK40084155A (en) Pharmaceutical compositions comprising alpelisib
JP2009507850A5 (cg-RX-API-DMAC7.html)
Patel Formulation and in Vitro Evaluation of Mucoadhesive Tablets of a Non-Steroidal Anti-Inflammatory Drug (Nsaid)
HK1174264B (en) Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate
TH94263A (th) องค์ประกอบของรูปแบบยาทางเภสัชกรรมชนิดใหม่ล่าสุดที่มีการปลดปล่อยแบบดัดแปรซึ่งประกอบด้วยตัวยับยั้งเอนไซม์ไซโคลออกซีเจเนส

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21848149

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3200071

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 140250140003001421

Country of ref document: IR

Ref document number: 2023531700

Country of ref document: JP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112023010014

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 202347041454

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 20237020732

Country of ref document: KR

Kind code of ref document: A

Ref document number: 112023010014

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20230523

WWE Wipo information: entry into national phase

Ref document number: 2023116517

Country of ref document: RU

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021848149

Country of ref document: EP

Effective date: 20230626

WWE Wipo information: entry into national phase

Ref document number: 202180091389.3

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2021848149

Country of ref document: EP

Effective date: 20230626

WWE Wipo information: entry into national phase

Ref document number: 2021388673

Country of ref document: AU

Ref document number: AU2021388673

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2021388673

Country of ref document: AU

Date of ref document: 20211118

Kind code of ref document: A

WWW Wipo information: withdrawn in national office

Ref document number: 202391591

Country of ref document: EA

WWG Wipo information: grant in national office

Ref document number: 2023116517

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2023116517

Country of ref document: RU